ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice

Figure 8

Neutralising ADAM19 does not affect the expression of ADAM19 in the liver. Representative photomicrographs showing ADAM19 immunohistochemistry performed on livers from HFD-fed mice administered either rabbit IgG control (a) or ADAM19 neutralising antibody (b). ADAM19 staining is cytoplasmic and brown in colour. 200x objective.

(a)

(b)